Drug: infliximab Quarter: 2016Q3
Total Drug/Injury Combinations: 643 Number of Pages: 33
DRUGNAME | PT | EventCount | |
---|---|---|---|
INFLIXIMAB, RECOMBINANT | Respiratory tract infection | 1 | view events |
INFLIXIMAB, RECOMBINANT | Rotavirus infection | 1 | view events |
INFLIXIMAB, RECOMBINANT | Sarcoidosis | 1 | view events |
INFLIXIMAB, RECOMBINANT | Septic shock | 1 | view events |
INFLIXIMAB, RECOMBINANT | Skin reaction | 1 | view events |
INFLIXIMAB, RECOMBINANT | Small cell lung cancer | 1 | view events |
INFLIXIMAB, RECOMBINANT | Staphylococcal bacteraemia | 1 | view events |
INFLIXIMAB, RECOMBINANT | Stenotrophomonas infection | 1 | view events |
INFLIXIMAB, RECOMBINANT | Syndactyly | 1 | view events |
INFLIXIMAB, RECOMBINANT | Systemic lupus erythematosus | 1 | view events |
INFLIXIMAB, RECOMBINANT | Teratogenicity | 1 | view events |
INFLIXIMAB, RECOMBINANT | Testicular seminoma (pure) | 1 | view events |
INFLIXIMAB, RECOMBINANT | Thrombotic thrombocytopenic purpura | 1 | view events |
INFLIXIMAB, RECOMBINANT | Toxic skin eruption | 1 | view events |
INFLIXIMAB, RECOMBINANT | Treatment failure | 1 | view events |
INFLIXIMAB, RECOMBINANT | Treatment noncompliance | 1 | view events |
INFLIXIMAB, RECOMBINANT | Tuberculosis of central nervous system | 1 | view events |
INFLIXIMAB, RECOMBINANT | Type IV hypersensitivity reaction | 1 | view events |
INFLIXIMAB, RECOMBINANT | Upper respiratory tract infection | 1 | view events |
INFLIXIMAB, RECOMBINANT | Vascular malformation | 1 | view events |
Total Drug/Injury Combinations: 643 Number of Pages: 33
NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)